NCT03140813View on ClinicalTrials.gov

An Initial Study of AZD7325 in Adults With Fragile X Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 16, 2018

Primary Completion Date

June 18, 2020

Study Completion Date

June 18, 2020

Conditions
Fragile X Syndrome
Interventions
DRUG

AZD7325 (High-Dose)

15mg PO BID

DRUG

AZD7325 (Low-Dose)

5mg PO BID

DRUG

Placebo oral capsule

Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03140813 - An Initial Study of AZD7325 in Adults With Fragile X Syndrome | Biotech Hunter | Biotech Hunter